RM-046

News alerts, weekly reports and conference planners

Company:

Revolution Medicines

Drug class:

KRAS Q61H inhibitor

‹

›

KRAS Q61H	Pancreatic Ductal Adenocarcinoma	KRAS Q61H	Pancreatic Ductal Adenocarcinoma	RM-046 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) RM-046 Sensitive : D AACR 2023 - 1wk	RM-046 Sensitive: D – Preclinical AACR 2023 - 1 week RM-046 Sensitive : D AACR 2023 - 1 week - (New D)
KRAS Q61H	Non Small Cell Lung Cancer	KRAS Q61H	Non Small Cell Lung Cancer	RM-046 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) RM-046 Sensitive : D AACR 2023 - 1wk	RM-046 Sensitive: D – Preclinical AACR 2023 - 1 week RM-046 Sensitive : D AACR 2023 - 1 week - (New D)

Associations
(2)